Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Federica Sabia has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Functional Recovery as a Survivorship Endpoint in Early-Stage NSCLC

    by Giovanni Leuzzi, Filippo Lococo, Beatrice Cosentino, Federica Sabia, Michele Ferrari, Alessandro Pardolesi, Alessia Stanzi, Jury Brandolini, Luigi Rolli, Matteo Calderoni, et al.

    Advances in screening, surgical techniques, perioperative care, and multimodality treatment have progressively expanded the population of long-term survivors with early-stage non-small cell lung cancer (NSCLC). However, disease-free survival does not necessarily correspond to complete functional recovery after curative-intent treatment. Many patients continue to experience persistent fatigue, dyspnea, reduced physical activity, impaired exercise tolerance, muscle loss, and deterioration in health-related quality of life despite adequate oncologic control. This narrative review discusses functional recovery as a survivorship endpoint in early-stage NSCLC, focusing on recovery trajectories, physiologic vulnerability, frailty, sarcopenia, rehabilitation, symptom burden, and emerging biologic frameworks such as allostatic load. Increasing evidence suggests that survivorship after NSCLC should not be interpreted exclusively according to recurrence or survival metrics, but also according to the ability to recover physiologic reserve, autonomy, and daily functioning after treatment. Functional recovery appears heterogeneous and influenced by multiple interacting factors, including baseline reserve, systemic inflammation, physical inactivity, behavioral adaptation, and cumulative stress burden. Rehabilitation strategies, structured symptom surveillance, and patient-reported outcomes may help identify vulnerable patients and improve long-term survivorship trajectories. Future survivorship models should probably integrate oncologic outcomes with longitudinal functional assessment to better characterize recovery patterns after treatment.


  • Open Access

    Leveraging Landmark Analysis for Tailored Surveillance in Stage I Non-Small-Cell Lung Cancer

    by Giovanni Leuzzi, Federica Sabia, Matteo Calderoni, Clarissa Uslenghi, Ugo Pastorino, Alfonso Marchianò, Michele Ferrari, Alessandro Pardolesi, Daniele Lorenzini, Giuseppe Lo Russo, et al.

    Background: Current guidelines for NSCLC follow-up lack specific recommendations on surveillance duration. This study aims to analyze survival and surveillance data in resected stage I NSCLC. Methods: We retrospectively reviewed 759 pathological stage I NSCLC (9thTNM ed.) patients with no history of lung cancer (LC) undergoing surgery from January 2003 to December 2018. Overall survival (OS), incidence of relapse (IR), and incidence of new primary LC (NP) were analyzed. Long-term effect of follow-up beyond 5 years was assessed by landmark analysis of OS, IR, and NP at 10 years, restricted to individuals alive without relapse or NP at 5 years (5-year event-free survivors, 5y-EFSs). Results: The rates of 10-year OS, 10-year IR, NP incidence, and 5y-EFSs were, respectively, 75%, 18%, 1.1%/year, and 59.1% (449 patients). Carcinoid IA/IB (0–10%) and adenocarcinoma IA/IB without lung nodules (LNs) (8–12%) had a similarly lower risk of relapse (p = 0.5088) compared to adenocarcinoma with LNs (p = 0.0191). Similarly, carcinoid (0–0.2%/year) and adenocarcinoma without LNs (0-0.3%/year) had the same lower incidence of NP (p = 0.8062) compared to patients with LNs (p < 0.0001). The group of 5y-EFSs had a conditional 10-year OS, IR, and NP incidence of 92%, 5%, and 0.8%/year. In 5y-EFSs, 10-year OS was better in carcinoid (100%) and adenocarcinoma (94%, p = 0.0009) patients; 10-year IR was lower in stage IA (4%) vs. IB (10%, p = 0.0444), and NP was lower in patients with no pre-surgery (0.5 vs. 1.5%/year, p = 0.0147) and no post-surgery LNs (0.6 vs. 1.1%/year, p = 0.0202). Conclusions: Based on our results, we propose a tailored surveillance strategy by de-escalating follow-up for low-risk patients while maintaining intensive monitoring for high-risk individuals.


  • Open Access

    Potential for AI as first reader in lung cancer screening

    by Roberta Eufrasia Ledda, Camilla Valsecchi, Federica Sabia, Gianluca Milanese, Maurizio Balbi, Luigi Rolli, Margherita Ruggirello, Nicola Sverzellati, Alfonso Vittorio Marchianò, Ugo Pastorino


  • Open Access

    The added value of an AI-based body composition analysis in a lung cancer screening population: preliminary results

    by Roberta Eufrasia Ledda, Federica Sabia, Camilla Valsecchi, Paola Suatoni, Gianluca Milanese, Luigi Rolli, Alfonso Vittorio Marchianò, Ugo Pastorino


  • Open Access

    Ultra-low dose computed tomography protocols using spectral shaping for lung cancer screening: Comparison with low-dose for volumetric LungRADS classification

    by Gianluca Milanese, Roberta Eufrasia Ledda, Federica Sabia, Margherita Ruggirello, Stefano Sestini, Mario Silva, Nicola Sverzellati, Alfonso Vittorio Marchianò, Ugo Pastorino


  • Open Access

    Automated Coronary Artery Calcium and Quantitative Emphysema in Lung Cancer Screening

    by Maurizio Balbi, Federica Msc Sabia, Roberta E. Ledda, Gianluca Milanese, Margherita Ruggirello, Mario Silva, Alfonso V. Marchianò, Nicola Sverzellati, Ugo Pastorino

    Purpose: To assess automated coronary artery calcium (CAC) and quantitative emphysema (percentage of low attenuation areas [%LAA]) for predicting mortality and lung cancer (LC) incidence in LC screening. To explore correlations between %LAA, CAC, and forced expiratory value in 1 second (FEV1) and the discriminative ability of %LAA for airflow obstruction. Materials and Methods: Baseline low-dose computed tomography scans of the BioMILD trial were analyzed using an artificial intelligence software. Univariate and multivariate analyses were performed to estimate the predictive value of %LAA and CAC. Harrell C-statistic and time-dependent area under the curve (AUC) were reported for 3 nested models (Modelsurvey: age, sex, pack-years; Modelsurvey-LDCT: Modelsurvey plus %LAA plus CAC; Modelfinal: Modelsurvey-LDCT plus selected confounders). The correlations between %LAA, CAC, and FEV1 and the discriminative ability of %LAA for airflow obstruction were tested using the Pearson correlation coefficient and AUC-receiver operating characteristic curve, respectively. Results: A total of 4098 volunteers were enrolled. %LAA and CAC independently predicted 6-year all-cause (Modelfinal hazard ratio [HR], 1.14 per %LAA interquartile range [IQR] increase [95% CI, 1.05-1.23], 2.13 for CAC ≥400 [95% CI, 1.36-3.28]), noncancer (Modelfinal HR, 1.25 per %LAA IQR increase [95% CI, 1.11-1.37], 3.22 for CAC ≥400 [95%CI, 1.62-6.39]), and cardiovascular (Modelfinal HR, 1.25 per %LAA IQR increase [95% CI, 1.00-1.46], 4.66 for CAC ≥400, [95% CI, 1.80-12.58]) mortality, with an increase in concordance probability in Modelsurvey-LDCT compared with Modelsurvey (P1 (P1, with %LAA enabling the identification of airflow obstruction with moderate discriminative ability.


  • Open Access

    Evaluation of Simplified Diet Scores Related to C-Reactive Protein in Heavy Smokers Undergoing Lung Cancer Screening

    by Federica Sabia, Alessandra Borgo, Alessandra Lugo, Paola Suatoni, Daniele Morelli, Silvano Gallus, Anna Villarini, Ugo Pastorino

    The aim of this study was to assess the relationship between adherence to a healthy diet, such as the Mediterranean diet (MedDiet), and C-reactive protein (CRP) in Italian heavy smokers undergoing an LDCT screening program (bioMILD trial), using scores calculated by simple questionnaires. Simple formats of food frequency questionnaires were administered to a sample of 2438 volunteers, and the adherence to a healthy diet was measured by the validated 14-point MEDAS and by two adaptations proposed by us: 17-item revised-MEDAS and 18-item revised-MEDAS. The OR of CRP ≥ 2 mg/L for 1-point increase in 14-point MEDAS score was 0.95 (95% CI 0.91–0.99), for 17-point score was 0.94 (95% CI 0.91–0.98), and for 18-point score was 0.92 (95% CI 0.88–0.97). These inverse associations remained statistically significant also after further adjustment for body mass index. These results showed the efficacy of simplified scores and their relationship with lower levels of CRP in a population of heavy smokers. This suggests that a targeted nutritional intervention might achieve a substantial reduction in CRP levels. The findings will be prospectively tested in a new randomized study on primary prevention during lung cancer screening.


  • Open Access

    Volumetric Measurements in Lung Cancer Screening Reduces Unnecessary Low-Dose Computed Tomography Scans: Results from a Single-Center Prospective Trial on 4119 Subjects

    by Gianluca Milanese, Federica Sabia, Roberta Eufrasia Ledda, Stefano Sestini, Alfonso Vittorio Marchianò, Nicola Sverzellati, Ugo Pastorino

    This study aims to compare the low-dose computed tomography (LDCT) outcome and volume-doubling time (VDT) derived from the measured volume (MV) and estimated volume (EV) of pulmonary nodules (PNs) detected in a single-center lung cancer screening trial. MV, EV and VDT were obtained for prevalent pulmonary nodules detected at the baseline round of the bioMILD trial. The LDCT outcome (based on bioMILD thresholds) and VDT categories were simulated on PN- and screenee-based analyses. A weighted Cohen’s kappa test was used to assess the agreement between diagnostic categories as per MV and EV, and 1583 screenees displayed 2715 pulmonary nodules. In the PN-based analysis, 40.1% PNs were included in different LDCT categories when measured by MV or EV. The agreements between MV and EV were moderate (κ = 0.49) and fair (κ = 0.37) for the LDCT outcome and VDT categories, respectively. In the screenee-based analysis, 46% pulmonary nodules were included in different LDCT categories when measured by MV or EV. The agreements between MV and EV were moderate (κ = 0.52) and fair (κ = 0.34) for the LDCT outcome and VDT categories, respectively. Within a simulated lung cancer screening based on a recommendation by estimated volumetry, the number of LDCTs performed for the evaluation of pulmonary nodules was higher compared with in prospective volumetric management.


  • Open Access

    Timeline of SARS-CoV-2 Spread in Italy: Results from an Independent Serological Retesting

    by Emanuele Montomoli, Giovanni Apolone, Alessandro Manenti, Mattia Boeri, Paola Suatoni, Federica Sabia, Alfonso Marchianò, Valentina Bollati, Ugo Pastorino, Gabriella Sozzi

    The massive emergence of COVID-19 cases in the first phase of pandemic within an extremely short period of time suggest that an undetected earlier circulation of SARS-CoV-2 might have occurred. Given the importance of this evidence, an independent evaluation was recommended by the World Health Organization (WHO) to test a subset of samples selected on the level of positivity in ELISA assays (positive, low positive, negative) detected in our previous study of prepandemic samples collected in Italy. SARS-CoV-2 antibodies were blindly retested by two independent centers in 29 blood samples collected in the prepandemic period in Italy, 29 samples collected one year before and 11 COVID-19 control samples. The methodologies used included IgG-RBD/IgM-RBD ELISA assays, a qualitative micro-neutralization CPE-based assay, a multiplex IgG protein array, an ELISA IgM kit (Wantai), and a plaque-reduction neutralization test. The results suggest the presence of SARS-CoV-2 antibodies in some samples collected in the prepandemic period, with the oldest samples found to be positive for IgM by both laboratories collected on 10 October 2019 (Lombardy), 11 November 2019 (Lombardy) and 5 February 2020 (Lazio), the latter with neutralizing antibodies. The detection of IgM and/or IgG binding and neutralizing antibodies was strongly dependent on the different serological assays and thresholds employed, and they were not detected in control samples collected one year before. These findings, although gathered in a small and selected set of samples, highlight the importance of harmonizing serological assays for testing the spread of the SARS-CoV-2 virus and may contribute to a better understanding of future virus dynamics.